AbbVie (NYSE:ABBV), Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) have entered into a collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19.
The focus will be on advancing the fully human,
neutralizing antibody 47D11 discovered by UU, EMC and HBM. This antibody
targets the conserved domain of the spike protein of SARS-CoV-2.
Under the terms of the collaboration, AbbVie will
support through the preclinical activities and preparations for
later-stage preclinical and clinical development work.
AbbVie will receive an option for the exclusive worldwide rights to license the antibody therapy.
https://seekingalpha.com/news/3580690-abbvie-to-develop-antibody-therapy-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.